de Almeida, Valéria
Seabra, Gabriela
Reis-de-Oliveira, Guilherme
Zuccoli, Giuliana S.
Rumin, Priscila
Fioramonte, Mariana
Smith, Bradley J.
Zuardi, Antonio W.
Hallak, Jaime E. C.
Campos, Alline C.
Crippa, José A.
Martins-de-Souza, Daniel http://orcid.org/0000-0003-3595-5846
Funding for this research was provided by:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Article History
Received: 20 January 2022
Accepted: 2 May 2022
First Online: 27 May 2022
Declarations
:
: JAC is a member of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) – National Health and Medical Research Council (NHMRC). JAC and JEH have received travel support to attend scientific meetings and personal consultation fees from BSPG-Pharm. JAC, JEH, and AWZ are co-inventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023,” Def. US number Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927; Mechoulam R, Zuardi AW, Kapczinski F, Hallak JEC, Guimarães FS, Crippa JAS, Breuer A). Universidade de São Paulo (USP) has licensed this patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1) and has an agreement with Prati-Donaduzzi to “develop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” JAC, JEH, AWZ are co-inventors of the patent “Cannabinoid-containing oral pharmaceutical composition, a method for preparing and using the same,” INPI on September 16, 2016 (BR 112018005423–2).